Predictive Performance of a Physiologically Based Pharmacokinetic Model of Busulfan in Children

REFERENCES

• McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009;5(8):957–969
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Bredius RG, Belitser SV, Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):231–241
   PubMed Web of Science ®Google Scholar
• McCune JS, Baker KS, Blough DK, Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013;53(3):264–275
   PubMed Web of Science ®Google Scholar
• Michel G, Valteau-Couanet D, Gentet JC, Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58(1):90–97
   PubMedGoogle Scholar
• Vassal G, Michel G, Espérou H Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113–123
   PubMed Web of Science ®Google Scholar
• Gibbs JP, Liacouras CA, Baldassano RN, Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466–1469
   PubMed Web of Science ®Google Scholar
• Hassan M, Oberg G, Bekassy AN, Pharmacokinetics of high dose busulfan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130–134
   PubMed Web of Science ®Google Scholar
• Salinger DH, Vicini P, Blough DK, Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol. 2010; 50(11):1292–300
   Google Scholar
• Nguyen L, Leger F, Lennon S, Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57(2):191–198
   PubMed Web of Science ®Google Scholar
• Lüpfert C, Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers. 2005;2(11):1462–1486
   Google Scholar
• Diestelhorst C, Boos J, McCune JS, Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults. Cancer Chemother Pharmacol. 2013;72(5):991–1000
   Google Scholar
• Hassan M, Oberg G, Ehrsson H, Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36(5):525–530
   Google Scholar
• Ehrsson H, Hassan M. Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol. 1984;36(10):694–696
   PubMed Web of Science ®Google Scholar
• Brookes P, Lawley PD. The reaction of mono- and di-functional alkylating agents with nucleic acids. Biochem J. 1961;80(3):496–503
   Google Scholar
• Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85(4):599–610
   PubMed Web of Science ®Google Scholar
• Boldt J. Use of albumin: an update. Br J Anaesth. 2010;104(3):276–284
   PubMed Web of Science ®Google Scholar
• Evans TW. Review article: albumin as a drug–biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16(Suppl 5):6–11
   PubMedGoogle Scholar
• Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996;24(9):1015–1019
   PubMed Web of Science ®Google Scholar
• Bredschneider M, Klein K, Mürdter TE, Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002;71(6):479–487
   Google Scholar
• Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20(5):543–549
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–512
   PubMedGoogle Scholar
• Oechtering D, Schiltmeyer B, Hempel G, Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anticancer Drugs. 2005;16:337–344
   PubMed Web of Science ®Google Scholar
• Murdter TE, Coller J, Claviez A, Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatographyelectrospray mass spectrometry. Clin Chem. 2001;47:1437–1442
   Google Scholar
• Grochow LB, Krivit W, Whitley CB, Busulfan disposition in children. Blood. 1990; 75(8):1723–1727
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Locatelli F, Buggia I, Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther. 1993;54(1):45–52
   Google Scholar
• Vassal G, Fischer A, Challine D, Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993;82(3):1030–1034
   Google Scholar
• Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004;31(2):109–134
   Google Scholar
• McCune JS, Bemer MJ, Barrett J, Busulfan in infants to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014;20(3):754–763
   Google Scholar
• Abbasi N, Vadnais B, Knutson JA, Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51(10):1429–1438
   PubMed Web of Science ®Google Scholar
• Bredschneider M, Klein K, Mürdter TE, Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002;71(6):479–487
   Google Scholar
• Zwaveling J, Press RR, Bredius RG, Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008;30:504–510
   PubMed Web of Science ®Google Scholar
• Ansari M, Lauzon-Joset JF, Vachon MF, Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010;45(2):261–267
   PubMed Web of Science ®Google Scholar